Arkolith/Insider Trading/PTGX/Form 4

Waddill William D.

DirectorProtagonist Therapeutics, Inc (PTGX) · full profile →Form 4 · filed Feb 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.7M
Net Open-Market Flow
-$1.7M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 6, 2026Option exercise(M)20K$8.31$166K28K
Feb 6, 2026Sell(S)20K$83.68$1.7M8K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 6, 2026Option exercise(M)20K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-011575) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML